1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

ADC Specialist LegoChem Takes Orion’s Hand As Long-Term Partner

26% Stake Should Ensure Competitive R&D

 
• By Jung Won Shin

Korean confectionery group Orion has become the biggest shareholder in compatriot ADC specialist LegoChem Biosciences, in a decisive step to move into the biotech sector as a new growth engine. For LegoChem, the alliance provides a friendly strategic partner and should enable a boost in R&D spending as it seeks to aggressively progress clinical trials and become a global player.

partnership
LegoChem’s Alliance With Orion In Line With Vision 2030 Ambitions • Source: Shutterstock

LegoChem Biosciences, Inc., a leading South Korean antibody-drug conjugate (ADC) platform company in the news recently for a major alliance, has generated more headlines through a surprise shareholding tie-up with a major domestic confectionery group, through which it will raise KRW548.5bn ($413m).

LegoChem conceded the stake sale to Orion was “sudden” but also “crucial” to the future of the company, and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from Focus On Asia